Search results for " Blocking"

showing 10 items of 52 documents

Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis

2019

Besides skin inflammation, patients with severe psoriasis suffer from an increased risk of cardiovascular mortality. IL-17A plays a central role in the development of psoriasis and might connect skin and vascular disease. The aim of this study was to clarify whether anti-IL-17A therapy could also ameliorate the vascular dysfunction associated with severe psoriasis. We analyzed three murine models with varying severities of psoriasis-like skin disease concerning their vascular function and inflammation: (i) K14-IL-17A(ind/+) mice with keratinocyte-specific IL-17A overexpression and an early-onset severe psoriasis-like phenotype; (ii) homozygous CD11c-IL-17A(ind/ind) and heterozygous CD11c-IL…

0301 basic medicineInflammationDermatologyDiseasemedicine.disease_causeBiochemistryProinflammatory cytokine03 medical and health sciencesMice0302 clinical medicinePsoriasis Area and Severity IndexPsoriasismedicineAnimalsHumansPsoriasisVascular DiseasesAntibodies BlockingMolecular BiologyAortaSkinInflammationImiquimodintegumentary systembusiness.industryVascular diseaseInterleukin-17Cell Biologymedicine.diseaseAngiotensin II3. Good healthMice Inbred C57BLDisease Models AnimalOxidative Stress030104 developmental biologyNeutrophil Infiltration030220 oncology & carcinogenesisImmunologyDisease Progression[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunotherapymedicine.symptombusinessReactive Oxygen SpeciesOxidative stress
researchProduct

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

2019

Abstract Purpose: Hyperprogression (HP), a paradoxical boost in tumor growth, was described in a subset of patients treated with immune checkpoint inhibitors (ICI). Neither clinicopathologic features nor biological mechanisms associated with HP have been identified. Experimental Design: Among 187 patients with non–small cell lung cancer (NSCLC) treated with ICI at our institute, cases with HP were identified according to clinical and radiologic criteria. Baseline histologic samples from patients treated with ICI were evaluated by IHC for myeloid and lymphoid markers. T-cell–deficient mice, injected with human lung cancer cells and patient-derived xenografts (PDX) belonging to specific mutat…

0301 basic medicineMaleCancer ResearchMyeloidLung NeoplasmsCD33Programmed Cell Death 1 ReceptorFc receptorMice NudeMice SCIDReceptors Fcnon-small cell lung cancer Hyperprogression immune checkpoint inhibitors.B7-H1 AntigenArticle03 medical and health sciences0302 clinical medicineImmunophenotypingAntineoplastic Agents ImmunologicalPD-L1Carcinoma Non-Small-Cell LungCell Line TumormedicineAnimalsHumansLung cancerAntibodies Blockingbiologybusiness.industryMacrophagesmedicine.diseaseXenograft Model Antitumor Assays3. Good healthImmunoglobulin Fc FragmentsTumor Burden030104 developmental biologymedicine.anatomical_structureNivolumabOncology030220 oncology & carcinogenesisbiology.proteinCancer researchImmunohistochemistryFemaleAntibodybusinessClinical Cancer Research
researchProduct

Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation.

2018

0301 basic medicineMaleImmunologyBradykininBradykinin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDownstream (manufacturing)Immunology and AllergyMedicineAnimalsHumansAngioedemaAntibodies BlockingMice KnockoutFactor XIIMice Inbred BALB Cbiologybusiness.industryPassive Cutaneous AnaphylaxisCell biologyMacaca fascicularis030104 developmental biologychemistry030220 oncology & carcinogenesisFactor XIIbiology.proteinAntibodyPassive Cutaneous AnaphylaxisbusinessComplement C1 Inhibitor ProteinThe Journal of allergy and clinical immunology
researchProduct

IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?

2016

ABSTRACT: Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are affected by Type 2 Diabetes (T2D), whose incidence has reached epidemic levels in recent years, thus increasing the health care costs. A better knowledge about the pathogenesis of these diseases as well as the mechanisms of action of drugs may allow both policy designers and physicians to choose the most effective treatments, thus lowering the costs. This review will focus on the role of Interleukin (IL)-1β in the pathogenesis of …

0301 basic medicinemedicine.medical_specialtyIL-1 blocking agentpathogenesimedicine.medical_treatmentInterleukin-1betaImmunologyType 2 diabetesComorbiditymacrophagePathogenesisArthritis Rheumatoid03 medical and health sciencesHealth careMedicineAnimalsHumansImmunology and AllergyRheumatoid arthritisIntensive care medicineAntibodies BlockingRheumatoid arthrititype 2 diabetebusiness.industryIL-1 blocking agentsIncidence (epidemiology)pathogenesisInterleukinImmunotherapybiologic drug; IL-1 blocking agents; IL-1β; macrophage; pathogenesis; Rheumatoid arthritis; type 2 diabetes; Immunology and Allergy; Immunologymedicine.diseaseComorbiditySettore MED/16 - Reumatologia030104 developmental biologyDiabetes Mellitus Type 2IL-1βRheumatoid arthritisImmunologyImmunotherapytype 2 diabetesbusinessbiologic drug
researchProduct

Hacia la ley europea del clima: las evaluaciones científicas y el futuro papel de las respuestas jurídicas de los estados miembros

2021

Los problemas climáticos son temas persistentes y omnipresentes dentro de las políticas y legislaciones contemporáneas, que exigen un enfoque interdisciplinario para promover soluciones jurídicas adecuadas para la complejidad del tema. Paradójicamente, las propagandas negacionistas, lejos de bloquear las acciones climáticas, las han propiciado, lo que ha llevado al establecimiento de un organismo científico super partes que reconociese las cuestiones climáticas a través de informes científicos avanzados: el Grupo Intergubernamental de Expertos sobre el Cambio Climático de la ONU (IPCC). Desde entonces, muchos países han usado los hallazgos del IPCC como base científica para desarrollar polí…

:CIENCIAS JURÍDICAS [UNESCO]Cambio Climático; Ley Europea del Clima; Pacto Verde Europeo IPCC; Derecho Público Comparadoas well as on the role that EU Members States? legislations will play in facing climate issues. Cambio climáticoIPCC2070-8157 22082 Revista Boliviana de Derecho 584568 2021 32 8055237 Hacia la ley europea del clima las evaluaciones científicas y el futuro papel de las respuestas jurídicas de los estados miembros ViolaEuropean Climate Lawinstead of blocking climate actionsleading to the establishment of a super partes scientific body that has acknowledged climate issues through the most advanced scientific reports: the UN Intergovernmental Panel on Climate Change (IPCC). Since thenPublic Comparative Law. 758 773demanding an interdisciplinary approach to foster legal solutions suitable for the complexity of the subject. Paradoxicallyhave fostered themEU Green DealPasquale Climate issues are persistent and pervasive topics within contemporary policies and legislationsmany countries have adopted the findings of the IPCC as scientific basis for developing strategic policies and legislation with the aim of combining adaptation and mitigation efforts. To this extentmainly focusing on the IPCC scientific basis and the proposed EU regulation related to climate changePacto Verde Europeo IPCCUNESCO::CIENCIAS JURÍDICASPacto Verde EuropeoCambio ClimáticoDerecho Público Comparadothe EU Green Deal and the future European Climate Law exemplify such contemporary attitude. This essay analyses the aforementioned assumptionsClimate changeLey Europea del Climanegationist claimsthe UN Intergovernmental Panel on Climate Change (IPCC). Since then [leading to the establishment of a super partes scientific body that has acknowledged climate issues through the most advanced scientific reports]
researchProduct

Perioperative nonspecific histamine release : a new classification by aetiological mechanisms and evaluation of their clinical relevance

1993

As a consequence of the performance of a randomized controlled clinical trial on perioperative histamine release and cardiovascular and respiratory disturbances, several types of increases in plasma histamine had to be distinguished instead of only two which existed at the beginning of the study: drug-induced allergic and pseudoallergic reactions. First of all, the new classification by aetiology (clinical epidemiology) was derived from a meta-analysis (secondary analysis) of the most recent literature. According to that histamine release in the perioperative period has several, different causes and is involved in several, different disease manifestations. A clear distinction (classificatio…

AdultMaleHistamine ReleaseDrug HypersensitivityIntraoperative Periodchemistry.chemical_compoundHumansMedicineAnesthesiaClinical significanceProspective StudiesAgedAnestheticsNeurosecretionbusiness.industryGeneral MedicinePerioperativeMiddle AgedPathophysiologyAnalgesics OpioidClinical trialAnesthesiology and Pain MedicinechemistryAnesthesiaEtiologyGastric acidFemalePremedicationNeuromuscular Blocking AgentsbusinessHistamineHistamineAnnales Françaises d'Anesthésie et de Réanimation
researchProduct

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease

2019

Abstract Context Scarce data exist regarding the relevance of stimulatory (TSAb) and blocking (TBAb) thyrotropin receptor antibodies in the management of Graves disease (GD). Objective To evaluate the clinical utility and predictive value of TSAb/TBAb. Design Prospective 2-year trial. Setting Academic tertiary referral center. Patients One hundred consecutive, untreated, hyperthyroid GD patients. Methods TSAb was reported as percentage of specimen-to-reference ratio (SRR) (cutoff SRR < 140%). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine thyrotropin (TSH, thyroid stimulating hormone) alone (cutoff > 40% inhibitio…

AdultMaleendocrine systemmedicine.medical_specialtyAdolescentendocrine system diseasesEndocrinology Diabetes and MetabolismGraves' diseaseClinical BiochemistryThyrotropinContext (language use)dilution analysisBiochemistryGastroenterologyThyrotropin receptorThyroid binding inhibitory immunoglobulinsYoung AdultMethimazoleEndocrinologyTSH-R stimulating antibodiesInternal medicineGraves hyperthyroidismmedicineHumansprospective trialProspective StudiesAutoantibodiesClinical Research Articlebiologybusiness.industryBiochemistry (medical)Receptors ThyrotropinMiddle AgedPrognosismedicine.diseaseeye diseasesGraves DiseaseTSH-R blocking antibodiesTiterEndocrinologyProspective trialbiology.proteinFemaleAntibodybusinessBiomarkersAcademicSubjects/MED00250Follow-Up Studiesmedicine.drugThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Repeated sugammadex reversal of muscle relaxation during lumbar spine surgery with intraoperative neurophysiological multimodal monitoring

2016

Intraoperative neurophysiological monitoring during spine surgery is usually acomplished avoiding muscle relaxants. A case of intraoperative sugammadex partial reversal of the neuromuscular blockade allowing adequate monitoring during spine surgery is presented. A 38 year-old man was scheduled for discectomy and vertebral arthrodesis throughout anterior and posterior approaches. Anesthesia consisted of total intravenous anesthesia plus rocuronium. Intraoperatively monitoring was needed, and the muscle relaxant reverted twice with low dose sugammadex in order to obtain adequate responses. The doses of sugammadex used were conservatively selected (0.1 mg/kg boluses increases, total dose neede…

AdultMalemedicine.medical_specialtymedicine.drug_classMuscle RelaxationContext (language use)Critical Care and Intensive Care MedicineSugammadexSugammadexAnestesia03 medical and health sciencesSpine surgery0302 clinical medicine030202 anesthesiologyIntraoperative neurophysiological monitoringHumansMedicineAnesthesiaAndrostanolsNeuromuscular blocking drugsRocuroniumMonitorizacion neurofisiologica intraoperatoriaNeuromuscular BlockadeLumbar Vertebraebusiness.industryMuscle relaxantCirugia de raquisFarmacos bloqueantes neuromuscularesNeuromuscular Nondepolarizing AgentsSurgeryAnesthesiology and Pain MedicineMuscle relaxationRocuronioAnesthesiaNeuromuscular BlockadeRocuroniumbusiness030217 neurology & neurosurgeryNeuromuscular Nondepolarizing Agentsgamma-Cyclodextrinsmedicine.drugIntraoperative neurophysiological monitoringRevista Española de Anestesiología y Reanimación
researchProduct

Beta-adrenergic blocking activity and haemodynamic effects in man of K� 1313, a new beta-adrenergic antagonist

1971

The beta-adrenergic blocking activity and haemodynamic effects of o-[2-hydroxy-3-(isopropylamino)-propoxy]-benzonitril (Ko 1313) have been studied in 22 patients. Antagonism of isoproterenol-induced tachycardia was used as a measure of the beta-adrenergic blocking activity. Ko 1313 1.0 mg had its maximum beta-adrenoceptor blocking effect 5–30 min after intravenous injection. Ko 1313 10.0 mg produced maximum betablockade 1–4 h after oral administration. 1.0 mg Ko 1313 injected intravenously had approximately the same beta-adrenergic blocking effect as 1.0 mg propranolol also given intravenously. After intravenous administration Ko 1313 was 3–4 times as potent as the same dose given orally. A…

AdultTachycardiamedicine.medical_specialtyCardiac outputAdolescentAdrenergic receptorCardiac VolumeAdrenergic beta-AntagonistsAdministration OralBlood Pressure1-PropanolPropranololPharmacologyElectrocardiographyHeart RateOral administrationInternal medicineNitrilesHeart ratemedicineHumansPharmacology (medical)Cardiac OutputPharmacologyBeta-adrenergic blocking agentPropylaminesbusiness.industryHemodynamicsIsoproterenolGeneral MedicineMiddle AgedAmino AlcoholsPropranololDose–response relationshipEndocrinologyInjections IntravenousSympatholyticsVascular Resistancemedicine.symptombusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Interruption of CD28-mediated costimulation during allergen challenge protects mice from allergic airway disease

2012

Background Allergic asthma is a T H 2-promoted hyperreactivity with an immediate, IgE, and mast cell–dependent response followed by eosinophil-dominated inflammation and airway obstruction. Objective Because costimulation by CD28 is essential for T H 2 but not T H 1 responses, we investigated the effect of selective interference with this pathway in mice using the models of ovalbumin and house dust mite–induced airway inflammation. Methods To study the role of CD28 in the effector phase of allergic airway inflammation, we developed an inducibly CD28-deleting mouse strain or alternatively used a CD28 ligand-binding site–specific mouse anti-mouse mAb blocking CD28 engagement. Results We show …

Allergic asthmaLymphocyte ActivationImmunoglobulin Emedicine.disease_causeT-Lymphocytes RegulatoryMice0302 clinical medicineAirway resistanceAllergenImmunology and AllergySensitizationMice Inbred BALB C0303 health sciencesbiologyAntibodies Monoclonalovalbuminrespiratory system3. Good healthmedicine.anatomical_structurecostimulationconditional CD28 knockout miceFemalemedicine.symptomImmunologyInflammation03 medical and health sciencesTh2 CellsCD28 AntigensRespiratory HypersensitivitymedicineAnimalsHumansAntigens DermatophagoidesLymphocyte CountAntibodies Blocking030304 developmental biologyHouse dust miteCD28-specific mAbbusiness.industryReceptor Cross-TalkAirway obstructionmedicine.diseasebiology.organism_classificationMice Mutant Strainsrespiratory tract diseasesDisease Models AnimalCTLA-4Immunologybiology.proteinbusiness030215 immunology
researchProduct